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University, Philadelphia, PennsylvaniaABSTRACT Liposomal drugs are a useful alternative to conventional drugs and hold great promise for targeted delivery in the
treatment of many diseases. Most of the liposomal drugs on the market or under clinical trials include cholesterol as a membrane
stabilizing agent. Here, we used liposomal CA4P, an antivascular drug, to demonstrate that cholesterol content can actually
modulate the release and cytotoxicity of liposomal drugs in a delicate and predictable manner. We found that both the rate of
the CA4P release from the interior aqueous compartment of the liposomes to the bulk aqueous phase and the extent of the
drug’s cytotoxicity undergo a biphasic variation, as large as 50%, with liposomal cholesterol content at the theoretically predicted
Cr, e.g., 22.0, 22.2, 25.0, 33.3, 40.0, and 50.0 mol % cholesterol for maximal superlattice formation. It appears that at Cr, CA4P
can be released from the liposomes more readily than at non-Cr, probably due to the increased domain boundaries between
superlattice and nonsuperlattice regions, which consequently results in increased cytotoxicity. The idea that the increased
domain boundaries at Cr would facilitate the escape of molecules from membranes was further supported by the data of dehy-
droergosterol transfer from liposomes to MbCD. These results together show that the functional importance of sterol superlattice
formation in liposomes can be propagated to distal targeted cells and reveal a new, to our knowledge, mechanism for how sterol
content and membrane lateral organization can control the release of entrapped or embedded molecules in membranes.INTRODUCTIONDuring the past decade there has been an increasing interest
in antivascular therapies that damage the existing tumor
microvasculature and cause a rapid and extensive shutdown
of tumor blood flow. The most prominent of these agents,
CA4, is a tubulin binding drug that disrupts the formation
of microtubules (1), which are essential for intracellular
protein trafficking, cell movement, and mitotic cell division.
Disruption of microtubule formation by CA4 thus reduces
cell proliferation and viability. CA4 preferentially binds
tubulin in endothelial cells of tumor blood vessels (2).
As a result, CA4 induces a pronounced reduction in
blood flow to solid tumors, leading to extensive tumor cell
necrosis (2–4).
CA4P is a prodrug of CA4. After administration, CA4P is
rapidly cleaved to CA4 by endogenous phosphatases. CA4P
is clinically more favorable than CA4 due to the signifi-
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0006-3495/12/05/2086/9 $2.00vascular shutdown within tumors at doses less than one-
tenth of the maximum tolerated dose (2). As with CA4,
the antivascular effect of CA4P has been demonstrated
both in animal models (5,6) and human cancer patients
(7,8). CA4P has been used in combination with conven-
tional chemotherapy and radiotherapy against a range of
tumor types, including breast cancer. An important limita-
tion of combretastatin is that it also significantly alters blood
flow in many normal tissues including heart, brain, spleen,
skin, and kidney (9). In the case of the brain and the heart,
even minute changes in blood flow may cause serious
harm to the patient.
In an attempt to reduce this potential side effect and
increase blood retention time of the drug, we have recently
employed liposomal CA4P in animal studies (10,11). The
advantages of using liposomal drugs as opposed to free
drugs are well documented in the literature (12,13) and
include the ability to selectively deliver liposomes to the
desired site in the body. Our previous study showed that
targeting anti-E-selectin conjugated immunoliposomes
loaded with CA4P to MCa-4 mammary tumors in mice
treated with therapeutic doses of ionizing radiation resulted
in a significant delay in tumor growth when compared with
other treatment groups such as free CA4P, tumor irradiation
alone, liposomal CA4P alone, and empty liposomes (10).
In this study, radiation was used to upregulate expression
of endothelial cell adhesion molecules (e.g., E-selectin),
which provided a means for targeting drugs to irradiated
tissue. Although this approach is very promising, the overalldoi: 10.1016/j.bpj.2012.03.063
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showed that the combination treatment with ionizing
radiation and immunoliposomes still allowed tumors to
increase in size over time, although the rate was reduced
significantly (10).
One conceivable method to improve this efficacy problem
is to optimize the liposomal formulation. In our previous
study (10), we used unilamellar vesicles composed of
hydrogenated soy phosphatidylcholine, cholesterol, and
distearoyl-L-a-phosphatidylethanolamine-N-[methoxy(poly-
ethylene glycol)-2000] (ammonium salt) (molar ratio:
50:45:5). In this formulation, as in many other liposomal
anticancer drugs, cholesterol was used as a membrane stabi-
lizing agent, but the cholesterol content (45 mol %) of the
liposome was chosen somewhat arbitrarily.
Many studies of cholesterol in liposomes have revealed
that cholesterol content in membranes is not a trivial issue.
In fact, cholesterol content is a critical factor involved in the
regulation of membrane properties. Specifically, it has been
established that cholesterol content affects physical and
biochemical properties of liposomal membranes in a nonmo-
notonic manner (reviewed in (14–16)). Many membrane
properties display a biphasic change at the Cr, at which the
extent of sterol superlattice in the plane of the membrane
reaches a local maximum (reviewed in (14,15) and discussed
later). In the range 19–52 mol % cholesterol, there are six
(namely, 20.0, 22.2, 25.0, 33.3, 40.0, and 50.0 mol %) Cr
values theoretically predicted for maximal superlattice
formation by the conventional sterol superlattice models
(17–20) or seven Cr values (namely, 20.0, 22.2, 25.0, 28.6,
33.3, 40.0, and 50.0 mol %) according to the recently
proposed sludgemodel (21). Prominent examples ofmultiple
biphasic changes in membrane properties at these Cr values
include the activities of phospholipase A2 (22), cholesterol
oxidase (23,24), and Na,K-ATPase (25,26) as well as the
partitioning of the antifungal drug nystatin (27), the rate
of free radical-induced sterol oxidation (28) and the interac-
tions of b-amyloid peptide with lipid membranes (29). It is
then logical to hypothesize that cholesterol content in lipo-
somal formulations could also affect the drug’s actions and
overall efficacies in a multiple biphasic manner in accor-
dance with the physical principles of sterol superlattice
formation (17,21).
In this study, we examined the effect of cholesterol
content in liposomal CA4P formulations on the drug’s
action on MCF-7 breast cancer cells. We employed a rather
unconventional approach, using small cholesterol mole frac-
tion increments (0.5 mol %) over a wide cholesterol mole
fraction range. Our findings indicate that both the rate of
the drug release from the interior aqueous compartment
of the liposomes to the bulk aqueous phase and the extent
of the drug’s cytotoxicity fluctuate with liposomal choles-
terol content. This variation is observed as a biphasic change
at Cr, fully in accordance with the physical principles of
sterol superlattice formation. It appears that at Cr, CA4Pcan be released from the liposomes more readily than at
non-Cr, probably due to the increased domain boundaries
between superlattice and nonsuperlattice regions, resulting
in increased cytotoxicity. This explanation is supported by
an independent experiment that monitored the initial rate
of sterol transfer from liposomes to MbCD, a water-soluble
macrocyclic molecule able to attract membrane sterols to its
hydrophobic cavity. Our data reveal a new, to our knowl-
edge, mechanism for how sterol content and membrane
sterol lateral organization can control the release of entrap-
ped or embedded molecules in membranes. These results
strongly suggest that cholesterol content should be carefully
considered in the context of sterol superlattice formation
when designing liposomal drugs for therapeutic treatment
of cancer and other conditions.MATERIALS AND METHODS
MCF-7 cell line
Human MCF-7 breast cancer cells (American Type Culture Collection,
Manassas,VA) were grown at 37C with 5% CO2 atmosphere using
complete growth medium composed of Dulbecco’s modified Eagle’s
medium (1, with 4.5g/L glucose, L-glutamine, and sodium pyruvate) sup-
plemented with 10% fetal bovine serum and 1% penicillin/streptomycin.
When ~80% confluency was reached, cells were detached using 0.25%
trypsin-EDTA, rinsed with phosphate-buffered saline, and collected
after centrifugation at 2000  g for 5 min at 25C. Cells were then resus-
pended into complete growth medium, plated into a 96-well microplate
(~10,000 cells per well) and maintained in a serum-containing medium
for >12 h, until the cells adhered to the wall of the microplate wells.Preparation of liposomal CA4P
CA4P-entrapped liposomes composed of cholesterol and POPC (Avanti
Polar Lipids, Alabaster, AL) were prepared. Calculated amounts of
POPC and cholesterol in chloroform were pipetted into test tubes and dried
under N2 until no visually detected solvent remained, and then further dried
overnight under high vacuum. The lipids were then reconstituted with
5.0 mL of 50 mM Tris-HCl buffer (pH 7.2) containing 30 mM CA4P
(synthesized as described in (10)), 0.02% NaN3, and 10 mM EDTA at
40C, flushed with N2 and vortexed for 3 min at 40C to form MLVs.
The MLVs were cooled to 4C for 30 min and then incubated at 40C
for 30 min. After being exposed to three cycles of heating/cooling to
allow for thorough mixing, vesicles were incubated for 4 days at room
temperature to achieve thermal equilibrium. During incubation, liposome
samples were protected from light and heat, flushed with argon gas,
and sealed with Teflon-lined screw caps to prevent lipid and drug autooxi-
dation (30).
Several sample sets of CA4P-entrapped cholesterol/POPC MLVs were
prepared. Every sample within the set contained the same absolute amount
of cholesterol, varying only in the cholesterol mole percent. This was
accomplished by varying the number of moles of POPC per tube while
leaving the number of moles of cholesterol constant. Cholesterol mole
percent was changed by 0.5 mol % for each sample. These sample sets
together cover the cholesterol mole fractions 18–52 mol %. In this range,
20.0, 22.2, 25.0, 28.6, 33.3, 40.0, and 50.0 mol % are the predicted Cr
for maximal superlattice formation.
LUVs were then prepared from MLVs by extrusion (Lipex Biomem-
branes, Vancouver, British Columbia, Canada). The MLVs were extruded
at 40C 10 times through two stacked 200-nm Nucleopore polycarbonate
membranes under N2 gas pressure (~150 psi) to form homogeneousBiophysical Journal 102(9) 2086–2094
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forR7 days before the cytotoxicity assay and drug release measurements.
The diameter of the extruded LUVs was ~180 nm as measured by photon
correlation spectroscopy using the Malvern Zetasizer HS-1000 spectrom-
eter (Worcestershire, UK). Our previous study (27) showed that the
sterol mole percents in vesicles before and after extrusion differ little
(%0.2 mol %). Thus, for convenience, the cholesterol mole percents in
MLVs were used to assess the relationship between liposomal cholesterol
content and drug release as well as the drug’s cytotoxicity in MCF-7 breast
cancer cells. The experimental errors for the cholesterol mole fractions have
been previously determined (using photometric and cholesterol oxidase
assays) to be 0.1–0.4 mol % (23,31).Separation of free CA4P from liposomal CA4P
Immediately before the cytotoxicity assay and the CA4P release experi-
ment, free CA4P was removed by a Sephadex G-50 gel filtration column
(8  105 mm). The column was loaded with 100 mL of 1 mM liposomal
lipids and eluted with 50 mM Tris-HCl buffer (pH 7.0) containing
10 mM EDTA. The elution profile was determined using light scattering
and CA4P fluorescence intensity. The fractions containing liposomes
with entrapped CA4P were pooled. The amount of CA4P in liposomes
was determined by first extracting 600 mL of the pooled fractions with
2 mL of chloroform/methanol (2:1, v/v). The entrapped CA4P (which is
water soluble) was released from liposomes and partitioned into the
aqueous phase. The absorbance at 300 nm of the aqueous phase was then
measured on a Perkin-Elmer lambda-25 spectrophotometer to determine
the amount of CA4P entrapped in the liposomes. The extinction coefficient
of CA4P in buffer (pH 7.0) at 300 nm is estimated to be 5640 M1cm1.Cytotoxicity assay
After the MCF-7 cells were treated with liposomal CA4P for 90 min at
37C, the dead cells (floating in the growth medium) were removed. The
cell proliferation assay was performed to determine the number of cells
remaining alive (defined as those still attached to the well). The assay was
performed at room temperature (~24C) using the CyQuant kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. Fluorescence
intensities at 530 nmweremeasured on a SpectraMaxM5microplate reader
(Molecular Devices, Sunnyvale, CA) with excitation at 485 nm. A standard
curve was constructed for each sample set using known amounts of MCF-7
cells countedwith a hemacytometer so that the fluorescence intensities could
be converted to the cell numbers. Typically, 0.5 nmole of CA4P in liposomes
was added to each of the 96-wells in themicroplate, which had ~10,000 cells
per well at time zero. Themaximumvolume of liposomal CA4P added to the
well was 50 mL and the total volume (growth medium plus vesicle disper-
sions in buffer) in each well was 200 mL.Release of entrapped CA4P from liposomes
At the concentration used in the liposomal CA4P preparation (30 mM), the
entrapped CA4P is in a self-quenched state. Leakage of entrapped CA4P
from liposomes was monitored by measuring the increase of CA4P fluores-
cence intensity due to the relief of self-quenching. Specifically, 200 mL of
liposomal CA4P dispersions collected from Sephadex G-50 (described
above) was mixed with 2 mL of 50 mM Tris buffer (pH 7.2) containing
10 mM EDTA and 0.02% NaN3. The samples were excited at 328 nm,
and the fluorescence intensity at 400 nm (Ft) was recorded as a function of
time on an ISS K2 fluorometer (Champaign, IL). At the end of each leakage
experiment, the sample was mixed with the detergent n-tetradecyl-b-D-
maltoside (Anatrace, Maumee, OH) (final concentration in the cuvette ¼
100mM) for 20min to release all the entrappedCA4P, providing themaximal
fluorescence intensity (Fmax). The equation F ¼A þ B(1  ekt), where k is
the rate constant of leakage, t is time, and A and B are constants, was usedBiophysical Journal 102(9) 2086–2094to fit the normalized fluorescence intensity (F ¼ Ft/Fmax). For each choles-
terol mole fraction examined, the leakage assay was repeated six times. At
Cr, three independently prepared samples were tested to assess reproduc-
ibility. The initial rate (R ¼ dF/dt(at t ¼ 0) ¼ kB) of CA4P leakage was
defined as the first derivative of F at time zero. Time zero is the time at which
fluorescence measurement was begun, i.e., 10 s after the samples exited the
Sephadex column. Because this deadtime (10 s) was the same for every
sample, comparing the R values among different samples is meaningful.
R is expressed as the change in normalized fluorescence intensity (DF) per
second.Release of sterol from liposomes to MbCD
A further experiment was conducted to test whether the biophysical prin-
ciple governing release kinetics in the CA4P leakage assay can be applied
to other molecules entrapped in liposomes. Here, we examined the sterol
transfer from liposomes to MbCD, a water-soluble macrocyclic compound
able to take up sterols from membranes. LUVs composed of POPC, DHE,
and Dansyl-PE (Avanti Polar Lipids) were examined. DHE (HPLC purified
Sigma, St. Louis, MO) was used as a fluorescent cholesterol analog and,
simultaneously, as a membrane component. DHE content was varied in
steps of 0.4 mol % in the range 18–52 mol %. The molar ratio of DHE/Dan-
syl-PE was kept constant (15:2) in all samples. The buffer used in this
experiment was 50 mM Tris containing 10 mM EDTA and 0.02% NaN3
at pH 7.2. To trigger the DHE transfer reaction, 40 mL of 600 mM
MbCD (in buffer) was added to liposome dispersions containing 12 nmol
of DHE. The final volume of the reaction mixture was 1.6 mL. The rate
of sterol transfer was monitored at room temperature (~24C) based on
the fluorescence resonance energy transfer between DHE (donor) and Dan-
syl-PE (acceptor) (32). When DHE is transferred from LUVs to MbCD,
energy transfer efficiency is decreased and, consequently, the fluorescence
intensity of Dansyl-PE (monitored at 500 nm on the ISS K2 fluorometer
using lex¼ 300 nm) decreases over time. The initial rate of the fluorescence
intensity decrease (inferentially, the initial rate of DHE transfer) was deter-
mined by a single exponential fit of the data and by evaluating the first
derivative of the fitted function at time zero.RESULTS AND DISCUSSION
Effect of cholesterol content in liposomal CA4P
on MCF-7 cytotoxicity
First, we used the CyQuant kit to demonstrate that although
liposomal CA4P can cause cytotoxicity in MCF-7 human
breast cancer cells, empty liposomes are not toxic to these
cells. Fig. 1 shows that liposomal CA4P (triangles) induced
a significant decrease in the number of live cells relative to
untreated cells (squares), especially during the first 90 min.
In contrast, treatment with liposomes alone (circles, Fig. 1)
did not result in any decrease in cell number. These data
indicate that the decrease in the number of live cells induced
by liposomal CA4P (triangles, Fig. 1) can only be attributed
to the microtubule disruptive effect of CA4P leading to cell
function shutdown, rather than the liposomes per se.
We then used the CyQuant kit to study the effect of
cholesterol content in liposomes on the CA4P-engendered
cytotoxicity in MCF-7 breast cancer cells. Five sample
sets of liposomes with different cholesterol mole percents
were examined (Fig. 2). In each sample set, the number of
cells and the amount of liposomal CA4P added to the cells
FIGURE 1 Effects of liposomes with and without CA4P on MCF-7 cell
growth. The y axis is the percentage of MCF-7 cells remaining in the micro-
plate wells relative to the number of untreated cells at the given time point
of the cell growth. The numbers of cells remaining in the wells were deter-
mined by the CyQuant kit. The error bars represent the standard deviations
of the cell numbers from six independently treated samples. At the time of
seeding MCF-7 cells, each well contained ~10,000 cells. Squares: cells
alone, without being treated with any liposomes or liposomal drugs or
free drugs. Circles: Cells treated with liposomes alone. Triangles: cells
treated with liposomal CA4P for different amounts of time. Liposomes
were composed of 30 mol % cholesterol and 70 mol % POPC.
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rials and Methods). Fig. 2 shows that the percentage of
MCF-7 cells remaining alive in the microplate wells after
treatment with liposomal CA4P for 90 min depends on lipo-
somal cholesterol content. Remarkably, the cytotoxicity ofFIGURE 2 Effect of liposomal cholesterol mole fraction on the number
of MCF-7 cells surviving in the microplate wells after a 90-min incubation
with liposomal CA4P. The error bars represent the standard deviations of
the cell numbers from six independently treated samples. Five sample
sets were examined: 18.0–23.2, 23.7–27.5, 32.3–34.3, 38.5–41.5, and
48.5–51.5 mol % cholesterol. The cell number reaches a local minimum
when cells were treated with liposomal CA4P at 20.0, 22.2, 25.0, 26.0,
33.3, 40.0, and 50.0 mol % cholesterol. The values of the theoretically pre-
dicted critical mole fractions for maximal sterol superlattice formation (Cr)
are indicated by arrows. Inset: The correlation between Cr and the observed
critical cholesterol mole fractions for minimal cell survival (Cs,min). r is the
correlation coefficient.liposomal CA4P against MCF-7 cells varies significantly
(as large as 50% change in cytotoxicity) with liposomal
cholesterol content in a well-defined alternating manner
(Fig. 2). The cytotoxicity, which is inversely proportional
to the number of live cells remaining in the microplate
well, is maximal when the cholesterol content in the lipo-
somes is at 20.0, 22.2, 25.0, 26.0, 33.3, 40.0, and 50 mol
% (designated as Cs,min, Fig. 2). Cs,min is defined as the
cholesterol mole fractions where the cell survival is minimal
(i.e., cytotoxicity is maximal). All these Cs,min values,
except for 26.0 mol %, are in excellent agreement with
the theoretically predicted critical sterol mole fractions Cr
(i.e., 20.0, 22.2, 25.0, 33.3, 40.0, and 50.0 mol %) for
maximal superlattice formation in liposomal membranes
(17–20). The relationship between Cr and Cs,min gives
a linear correlation coefficient r ¼ 0.999 (considering all
the Cs,min values obtained; inset in Fig. 2).Effect of cholesterol content on the release
of CA4P from liposomes
To gain a mechanistic understanding of the results shown in
Fig. 2, we have used the intrinsic fluorescence of CA4P to
develop an assay to monitor the spontaneous release of
entrapped CA4P from the liposomes (see Materials and
Methods). As illustrated in Fig. 3, the release of entrapped
CA4P results in fluorescence intensity enhancement due to
the relief of self-quenching. More importantly, Fig. 3 shows
that the initial rate of the fluorescence intensity change at Cr
(e.g., 40.0 mol %) is much faster than that from the lipo-
somes at the neighboring non-Cr (e.g., 41.0 and 39.5 mol %).
R is expressed as the change in normalized fluorescence
intensity (DF) per second. The initial rate of the drug
release (R) can be expressed as the change in normalized
fluorescence intensity (DF) per second (see Materials and
Methods).FIGURE 3 Illustration of the effect of cholesterol mole fraction on the
time variation of CA4P fluorescence intensity (F) from LUVs composed
of POPC/cholesterol. This graph shows the data obtained from three
different cholesterol mole fractions at room temperature. 40.0 mol % is
a Cr value, whereas 39.5 and 41.0 mol % are nonCr values.
Biophysical Journal 102(9) 2086–2094
FIGURE 5 Effect of cholesterol mole fraction on the initial rate (R) of
CA4P release from liposomes composed of cholesterol and POPC at
24C. The error bars at Cr (labeled with *) were calculated from three inde-
pendently prepared samples. The vertical bars at non-Cr represent the stan-
dard deviations of multiple experiments (n R 3) from the same sample.
Four sample sets were examined: 19.0–26.5, 32.3–34.3, 38.5–41.5, and
48.5–51.5 mol % cholesterol. R reaches a local maximum at 20.0, 22.2,
25.0, 33.3, 40.0, and 50.0 mol % cholesterol (designated as CR,max). The
values of Cr are indicated by arrows. The inset shows the correlation
between Cr and CR,max.
2090 Venegas et al.To directly compare CA4P release data with the cytotox-
icity data, which were obtained at 37C, some of the drug
release experiments were conducted at 37C. The results
are presented in Fig. 4, where two sample sets covering
two theoretical Cr values (33.3 and 40.0 mol %) was exam-
ined. In this figure, local maxima in R are seen at 33.3 and
40.5 mol % cholesterol, which are in good agreement with
the theoretical Cr values. The drug release experiment at
37C has a minor technical problem. That is, the liposomal
drug isolated from the Sephadex G-50 column (water jack-
eted at 37C) was exposed to room temperature briefly
(10 s) before the fluorescence measurements (at 37C).
To demonstrate that this brief temperature perturbation
does not lead to any significant changes to our conclusion,
we did the drug release experiment at room temperature
(24C) as well (Fig. 5). We found that, at 24C, the initial
rate of CA4P release varies with cholesterol content in
an alternating manner, showing local maxima at 20.0,
22.2, 25.0, 32.8, 40.0, and 50.0 mol % (Fig. 5). Within
the experimental errors (~0.1–0.4 mol %), these cholesterol
mole fractions (designated as CR,max) are in good agreement
with the theoretical Cr values (r ¼ 0.999; inset of Fig. 5).
Our previous experiments (23,33) showed that biphasic
changes in membrane properties at Cr would occur as long
as the membrane was above the gel-to-liquid crystalline
phase transition temperature of the matrix lipids and
below ~60C, where thermal-induced randomization would
dominate. Statistical mechanical calculations also showed
that the lower mole fraction limit where the calculated
phase boundary begins to deviate from the measured phase
boundary decreases with decreasing temperature (21).
For cholesterol/DMPC mixtures, those lower limits areFIGURE 4 Illustration that a biphasic change in the initial rate (R) of
CA4P release with liposomal cholesterol content. Temperature ¼ 37C.
The vertical bars at non-Cr represent the standard deviations of multiple
experiments (n R 3) from the same sample. The error bars at Cr (33.3
and 40.0 mol % cholesterol) were calculated from three independently
prepared samples. R reaches a local maximum at 33.3 and 40.4 mol %
cholesterol in these two cholesterol mole fraction regions (32.3–34.3 and
38.5–41.5 mol % cholesterol) examined.
Biophysical Journal 102(9) 2086–209416.7 mol % at 45C and 8 mol % at 35C (21). Conceivably,
the lower mole fraction limit for sterol superlattice forma-
tion at 24C would be much lower (<8 mol %) than the
mole fractions examined in this study (18–52 mol %).
Hence, the selection of 24C is justified in two aspects. First,
this method avoids any temperature perturbation to the
membrane during the drug release experiment; second, it
maintains the membrane in a physical state that is expected
to sustain sterol superlattice formation. Because the 24C
(room temperature) experiment is more convenient, we
obtained more data points and covered a wider mole fraction
range for 24C than for 37C. However, the final conclusion
is the same, that is, that R is maximal at or near Cr.
A biphasic change at 26 mol % cholesterol was observed
in the cytotoxicity measurements (Fig. 2) but not in drug
release (Figs. 4 and 5). As mentioned earlier, 26 mol % is
not one of the predicted critical mole fractions for maximal
superlattice formation. We speculated that the dip in cell
survival rate at 26 mol % (Fig. 2) may come from the coex-
istence of two different sterol superlattices with two
different compositions, for example, 25.0 and 33.3 mol %,
as discussed previously (22,30,31). In our previous studies
of sterol superlattices, the dips or peaks in membrane
properties or membrane-mediated processes at ~26 mol %
were observed only in rare cases (22,30,31). In contrast,
the dips/peaks at 20.0, 22.2, 25.0, 33.3, 40.0, and 50.0
were observed every time. Thus, the lateral structure
corresponding to 26 mol % is likely to be metastable.
The metastability may explain why a biphasic change at
26 mol % appeared in one assay but not in the other
experiment.
FIGURE 6 Schematic drawing illustrating the concept that the rate of
spontaneous release of entrapped CA4P varies with the lipid packing main-
tained in different membrane regions. In a cholesterol-containing lipid
membrane, superlattice and nonsuperlattice regions always coexist (17).
The interfacial areas between superlattice and nonsuperlattice domains
are more defective, possessing more void space and volume fluctuations.
Hence, the spontaneous release of CA4P through the interfacial regions
is faster than through other regions of the membranes.
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model
The biphasic change in the initial rate of CA4P release at Cr
can be explained using either the conventional sterol super-
lattice model (14,15,17) or the recently proposed sludge
model (21). The conventional sterol superlattice model
proposes that cholesterol can be organized in a regular
lattice within the matrix lattice formed by lipid acyl chains
and sterol molecules. The sludge model proposes that a rigid
cluster is formed by a cholesterol molecule and phospho-
lipid molecules that are condensed to the cholesterol.
Rigid clusters of similar size tend to form aggregates, in
which cholesterol molecules are regularly distributed into
superlattices. Both models contend that, at any given choles-
terol mole fraction, sterol superlattice (regular) regions
always coexist with nonsuperlattice (irregular) regions
(14,17,21,34). However, at the Cr, the ratio of superlattice/
nonsuperlattice domains reaches a local maximum
(14,17,21,30). In the range 19–52 mol % cholesterol, there
are six (namely, 20.0, 22.2, 25.0, 33.3, 40.0, and 50.0 mol %)
Cr values theoretically predicted for maximal superlattice
formation by the conventional sterol superlattice model
(17–20) or seven Cr values (namely, 20.0, 22.2, 25.0,
28.6, 33.3, 40.0, and 50.0 mol %) according to the sludge
model (21).
At Cr there should be a large increase in the interfacial
area between the regular and irregular regions. This point
can be understood as follows. First, there is a sharp biphasic
change (reaching a maximum) in the area covered by super-
lattices (Areg) at Cr as calculated by either a statistical
mechanical model of cholesterol and phospholipids or by
using the nystatin partition coefficient (21,23,27). Second,
using statistical thermodynamics, we have calculated the
cooperativity energy of superlattice lattice formation (u)
at each of the critical sterol mole fractions examined in
this study (21). All the u values at Cr (325.9 cal/mol for
20.0 mol %; 319.2 cal/mol for 22.2 mol %, 312.4 cal/mol
for 25.0 mol %, 297.8 cal/mol for 33.3 mol %, 289.6 cal/mol
for 40.0 mol %; 280.1 cal/mol for 50.0 mol %) are smaller
than the thermal energy unit, kT (21). Because of the
small u values, there should be numerous aggregates (rather
than a single large domain) of rigid clusters (superlattices)
with a broad size distribution at Cr, according to the work
of Sugar (35). Taken together, the perimeter of the regular
region (thus, the interfacial area between the regular and
irregular regions) must reach a local maximum at Cr as
previously proposed (30).
Compared to other regions in the membrane, the interfa-
cial areas between regular (superlattice) and irregular (non-
superlattice) domains should be more defective, possessing
more void space and volume fluctuations. Membrane
defects or volume fluctuations could promote solute perme-
ation (36) and channel formation (37). Hence, the sponta-
neous release of CA4P through the domain interfacialregions should be faster than through other regions of the
membranes. This concept is schematically described in
Fig. 6. Because the interfacial regions between superlattices
and nonsuperlattices are maximal at Cr (30), the rate of
CA4P leakage is faster at Cr than that at the neighboring
non-Cr, thus producing a biphasic change in R at Cr (Figs.
3–5). As such, our CA4P release data (Figs. 3–5) can be
satisfactorily explained by the sterol superlattice models.
Because the release of the entrapped CA4P from lipo-
somes into the aqueous phase is faster at Cr, liposomal
CA4P exhibits a more pronounced cytotoxic effect on
MCF-7 cells at Cr than at the neighboring non-Cr (Fig. 2).
In each of the samples within the same sample set for the
cytotoxicity experiment, the cell number at time zero
(e.g., 10,000) and the amount of liposomal CA4P added
(e.g., 0.5 nmole CA4P) were fixed. According to the
conventional wisdom, one would predict the same cell
survival rate for all the samples examined. However, our
data (Fig. 2) show that this is not the case. Here, we demon-
strate that the cell survival rate varies by as much as 50%
with the cholesterol content of the liposomal drug in a
biphasic manner, reaching a local minimum at Cr (Fig. 2).
These results are worth noting and can be best interpreted
by the concept of sterol superlattice formation.Release of DHE from liposomes to MbCD
In addition to CA4P, other molecules that are entrapped
could also escape from liposomes more easily at Cr than
at non-Cr, because at Cr the interfacial regions betweenBiophysical Journal 102(9) 2086–2094
2092 Venegas et al.superlattices and nonsuperlattices are maximal and because
the interfacial regions are more defective, as mentioned
earlier. To test if this is true, we have studied the rate of
transfer of DHE from LUVs composed of DHE/POPC/
Dansyl-PE to MbCD. It has been suggested that interfaces
between gel and liquid-crystalline domains favor lipid trans-
fer between membranes (38).
Fig. 7 shows that the initial rate of the DHE transfer
indeed varies with sterol content in the original membrane
in a biphasic manner, reaching local maxima at 20.4, 22.2,
24.6, 26.0, 28.4, 33.3, 40.4, and 50.0 mol %. Within the
experimental errors (0.1–0.4 mol %), these values, except
for 26.0 mol % (discussed earlier), are in good agreement
with the theoretically predicted Cr values. Thus, our results
(Fig. 7) show that the rate of DHE transfer from DHE/
POPC/Dansyl-PE LUVs to MbCD is governed by the extent
of sterol superlattice in the liposomal membrane, a conclu-
sion similar to that obtained from the CA4P release experi-
ment (Figs. 4 and 5). Note that, upon addition of MbCD to
trigger sterol transfer, the membrane lateral organization is
perturbed; thus, we only determined the initial rate of sterol
transfer so that we could link the transfer data to membrane
lateral organization. Furthermore, note that in the measure-
ments of CA4P release and cytotoxicity (Figs. 2, 4, and 5)
we did not scan the concentration range around 28.6 mol %,
an additional critical sterol mole fraction for maximal super-
lattice formation predicted by the newly proposed sludge
model (21).Biophysical and pharmaceutical implications
This study demonstrates that the functional importance of
cholesterol superlattice in liposomes can be manifested
in targeted cells. Cholesterol lateral organization in the
membrane is a long-standing conundrum that is of funda-
mental importance in understanding the role of cholesterol
in membranes or cells. Considerable spectroscopic and
functional evidence supporting the superlattice model has
been reported in the literature (reviewed in (14,20)). ForFIGURE 7 Effect of liposomal sterol content on the initial rate of DHE
transfer from liposomes to MbCD. Temperature ¼ 24C.
Biophysical Journal 102(9) 2086–2094the functional evidence, we and others have previously
reported that the activities of membrane surface acting
enzymes and membrane-bound proteins, such as phospholi-
pase A2 (22), cholesterol oxidase (23), and Na, K-ATPase
(25), as well as the rate of free radical-induced sterol oxida-
tion (28,39) and the partitioning of the antifungal drug
nystatin into membranes (27) are regulated by the extent
of sterol superlattice in the membrane. Here, we show that
the release of entrapped CA4P and the cytotoxicity of lipo-
somal CA4P against breast cancer cells are also regulated by
the extent of sterol superlattice in the liposomes. These
results provide the most compelling functional evidence
for sterol superlattice formation and show that the functional
importance of sterol superlattice formation in liposomes can
be propagated to distal targeted cells.
This work is also highly significant from a pharmaceutical
perspective. There is increasing evidence showing that lipo-
somal drugs have significant advantages over free drugs for
many therapeutic and prophylactic purposes (12,13). To
date, >20 liposomal anticancer drugs are on the market or
under clinical trials (40–42). About 75% of them include
cholesterol as a major component (40,42). Cholesterol has
been used mainly because it can increase liposome stability
in circulation and other tissues and because in some cases
(43) it was required for the liposomal drug to exhibit strong
antiproliferation activity toward tumor cells. Previous
studies have shown that the amount of cholesterol in lipo-
somal drugs is important. For example, a patent application
for a doxorubicin liposomal formulation (U.S. patent
4898735) claimed that 20 mol % cholesterol caused a 2–3
times increase in drug retention, but no additional improve-
ment was seen up to 50 mol % cholesterol. Another study
showed that increasing cholesterol in the CA4 liposomal
formulation decreased drug loading and drug leakage from
the liposomes (44). However, these studies used large
cholesterol increments (10–30 mol %). When using large
mole fraction increments, the actual cholesterol dependence
of liposomal drug activity could elude detection or the result
may lead to an erroneous conclusion as demonstrated in
(30). Furthermore, there is currently no rational, science-
based method to select the optimal amount of cholesterol.
In this study, we demonstrate that cholesterol does not
simply serve as a membrane stabilizing agent. By using
small cholesterol mole fraction increments (0.5 mol %),
we found that cholesterol content can actually modulate
the release and the cytotoxicity of liposomal CA4P in accor-
dance with the concept of sterol superlattice. Hence, the
concept of sterol superlattice can be employed to optimize
the cholesterol content in liposomal drug formulations to
achieve higher efficacy for therapeutic treatment of cancer
and other conditions. This approach has the potential to
impact liposomal drug formulations already in use as well
as to aid in predicting the most effective concentration of
cholesterol in new formulations without time-consuming
trial and error.
Role of Sterol Superlattice in Drug Release and Cytotoxicity 2093FUTURE STUDIES
The purpose of this work is to use cholesterol/POPC lipo-
somal CA4P and MCF-7 cancer cells to demonstrate a
new, to our knowledge, physical principle governing the
interactions of liposomal drugs with cells. This physical
principle should be applicable to many different liposome
systems, different types of cells, and different therapeutic
agents, especially water-soluble drugs with sizes similar to
CA4P (e.g., doxorubicin, DMXAA (5,6-dimethylxanthe-
none-4-acetic acid) and AVE8026 ((2S)-2-Amino-3-
hydroxy-N-[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)
ethenyl]phenyl]propanamide)).
Although our present data show maximal drug release and
cytotoxicity at the Cr for greatest superlattice formation, we
cannot claim at this time that liposomal CA4P at Cr is the
best formulation for in vivo applications. Studies in animal
models are theobvious next step,whichwill generate informa-
tion on circulation times, biodistribution, and tumor-growth
inhibition with liposomal formulations containing different
mol % of cholesterol. If the time for liposomes to reach the
target, i.e., tumors, is much shorter than the time for sponta-
neous drug release in the circulation, then there is a high possi-
bility that liposomal CA4P is most effective in suppressing
cancer cell growth when the liposomal cholesterol content is
at Cr due to increased cytotoxicity. On the other hand, if the
time to reach the target is much longer than the time for
spontaneous drug release, then it is likely that liposomal
CA4P is least effectivewhen the liposome cholesterol content
is at Cr. This predicted reduction in efficacy is due to leakage
of the drug in areas other than the target region, leading to
collateral damage to normal tissues. Nevertheless, our results
reveal a new, to our knowledge, biophysical concept for
designing liposomal drugs for cancer treatment. This strategy,
when used in combination with radiation/chemotherapy and
targeted delivery, may significantly increase the overall thera-
peutic efficacy of liposomal anticancer drugs.
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